BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 7, 2003
View Archived Issues
New p38 inhibitors with utility in COPD
Read More
AstraZeneca describes new immunosuppressants with potential in respiratory disorders
Read More
Bayer scientists present novel bradykinin B1 antagonists for use as analgesic agents
Read More
Dopamine D2 receptor partial agonists prepared and tested at Wyeth
Read More
New modulators of vasopressin and/or oxytocin receptors covered by Sanofi-Synthelabo patent
Read More
Series of melanocortin MC4 receptor agonists in early development at Merck
Read More
Dr. Reddy's describes novel antidiabetic agents
Read More
New MRI agents designed at Bracco
Read More
NicOx reports substantial progress for 2002
Read More
New data on adefovir dipivoxil in the long-term treatment of chronic hepatitis B
Read More
Aphton presents phase III results for G17DT to foreign regulatory authority
Read More
Cardiome reviews 2002, presents outlook for 2003
Read More
Mechanisms underlying effects of zoledronic acid on prostate cancer bone metastases
Read More
AVAC for atopic dermatitis completes phase I testing in children
Read More
Ranexa NDA accepted for filing
Read More
NIAID to fund GTC clinical production of MSP-1 malaria vaccine
Read More
Oral tazarotene completes phase III studies
Read More
MVA-BN nef shows promise in HIV trial
Read More
Pennsaid approved in Italy
Read More
FDA panel recommends approval for Factive in respiratory tract infections
Read More
Argatroban meets primary endpoints in ARGIS-I study
Read More
Lercanidipine 20 mg approved in Europe
Read More
Dryvax side effects reduced by prior immunization with NYVAC or MVA
Read More
NIH licensing opportunity: gp64 pseudotyped vectors and uses thereof
Read More
Discovery of potent and selective 5-HT7 receptor antagonists
Read More
A-349821 characterized as potent, selective, orally available H3 receptor antagonist
Read More
GVAX enhances antitumor immunity in certain patients with advanced NSCLC
Read More